{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-124655","form_type":"8-K","ticker":"ATOS","cik":"0001488039","company_name":"ATOSSA THERAPEUTICS, INC.","filed_at":"2024-11-12T23:59:59+00:00","discovered_at":"2026-05-14T18:03:08.567998+00:00","generated_at":"2026-05-30T01:46:55.705736+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Atossa Therapeutics reports Q3 2024 results, highlights positive Phase 2 data for (Z)-endoxifen","bullets":["Announced positive topline from KARISMA-Endoxifen Phase 2: MBD reductions of 19.3% (1 mg) and 26.5% (2 mg) vs placebo.","Preliminary I-SPY 2 EOP analysis: 95% (19/20) of patients met primary endpoint with >75% treatment completion.","First patient dosed in combination trial of (Z)-endoxifen with abemaciclib (VERZENIO) in ER+/HER2- breast cancer.","Ended Q3 2024 with $74.8 million cash and equivalents, no debt.","Received new U.S. Patent No. 12,071,391 covering (Z)-endoxifen compositions."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-124655","json":"https://secwatch.observer/filing/0000950170-24-124655.json","markdown":"https://secwatch.observer/filing/0000950170-24-124655.md","text":"https://secwatch.observer/filing/0000950170-24-124655.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1488039/000095017024124655/0000950170-24-124655-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1488039/000095017024124655/atos-20241112.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-30T01:46:55.705736+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}